Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients
Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain
Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
This observational or N/A phase trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Korea Otsuka Pharmaceutical Co., Ltd. leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Korea Otsuka Pharmaceutical Co., Ltd.
- Ministry of Health & Welfare, Korea
- Samsung Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .